Poorer Survival in Patients with Cecum Cancer Compared with Sigmoid Colon Cancer DOI Creative Commons
Shibo Song, Jiefu Wang, Heng Zhou

et al.

Medicina, Journal Year: 2022, Volume and Issue: 59(1), P. 45 - 45

Published: Dec. 27, 2022

Background and Objectives: An increasing number of studies have shown the influence primary tumor location colon cancer on prognosis, but prognostic difference between cancers at different locations remains controversial. After comparing differences left-sided right-sided cancer, study subdivided into three parts, respectively, explored which parts had most significant differences, with aim to further analyze significance cancer. Materials Methods: Clinicopathological data patients who underwent radical surgery from Surveillance, Epidemiology, End Results Program database were analyzed. The was divided two groups (2004–2009 2010–2015) based time intervals. Two survival by using Cox regression analyses. verified in analyses after propensity score matching. Results: Patients worse cancer-specific overall compared Survival cecum sigmoid found be among six both 2004–2009 2010–2015 periods. matching, multivariate showed that an independent unfavorable factor for specific (HR [95% CI]: 1.11 [1.04–1.17], p = 0.001 2004–2009; HR 1.23 [1.13–1.33], < 1.09 [1.04–1.14], Conclusions: indicates prognosis is than colon. current dichotomy model (right-sided vs. colon) may inappropriate

Language: Английский

Prognostic factors and survival disparities in right-sided versus left-sided colon cancer DOI Creative Commons
Mohammad Asghari Jafarabadi, Simon Wilkins, John‐Paul Plazzer

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: May 29, 2024

Abstract Right-sided colon cancer (RCC) and left-sided (LCC) differ in features outcomes because of variations embryology, epidemiology, pathology, prognosis. This study sought to identify significant factors impacting patient survival through Bayesian modelling. Data was retrospectively analysed from a colorectal neoplasia database. on demographics, perioperative risks, treatment, mortality, patients who underwent surgery January 2010 December 2021. involved 2475 patients, with 58.7% having RCC 41.3% LCC. had notably higher mortality rate, their overall (OS) rates were slightly lower than those LCC (P < 0.05). stages I–IV consistently exhibited worse OS relapse-free (RFS) Factors like age, BMI, ASA score, stage, comorbidities associations RFS. Poor moderate differentiation, lymph node yield, organ resection linked while receiving chemotherapy; BMI levels elective associated better (all P Our reveals key differences between LCC, emphasising the impact survival. These findings could inform personalised treatment strategies for patients.

Language: Английский

Citations

8

Prognostic value of preoperative combined with postoperative systemic immune-inflammation index for disease-free survival after radical rectal cancer surgery: a retrospective cohort study DOI Open Access
Jiayi Sun,

Ruiling Yang,

Huimin Wu

et al.

Translational Cancer Research, Journal Year: 2024, Volume and Issue: 13(1), P. 371 - 380

Published: Jan. 1, 2024

Background: Colorectal cancer (CRC) ranks highly in malignant tumor incidence and mortality rates, severely affecting human health. The predictive value of the systemic immune-inflammation index (SII) CRC prognosis is gaining attention, but there limited research on combined preoperative postoperative SII. This study aims to explore prognostic SII disease-free survival (DFS) patients undergoing radical surgery for rectal cancer. Methods: We enrolled 292 with who underwent resection at Affiliated Hospital Xuzhou Medical University from May 2018 September 2020, along regular follow-ups document DFS. Patients' complete blood cell counts were assessed before between 21–56 days postoperatively. Calculating SII, categorized into four groups based optimal cutoff values: (I) low-low group (preoperative <449.325 <568.13); (II) high-low ≥449.325 (III) low-high ≥568.13); (IV) high-high ≥568.13). receiver operating characteristic (ROC) curve analysis evaluated prediction efficacy preoperative, postoperative, Kaplan-Meier generated DFS curves, Cox regression determined factors. Results: With a median follow-up 41 months, 65.4% (191/292) reached clinical pathological features are balanced comparable (P>0.05). area under ROC was 0.668 [95% confidence interval (CI): 0.6–0.737], 0.696 (95%CI: 0.63–0.763), 0.741 (95% CI: 0.681–0.802), respectively. After adjusting confounding factors such as adjuvant therapy, differentiation, vascular invasion, neural tumor-node-metastasis (TNM) stage, carcinoembryonic antigen (CEA), carbohydrate 19-9 (CA19-9), significant differences observed [hazard ratio (HR) =2.403; 95% 1.255–4.602; P=0.008], (HR =5.058; 2.389–10.71; P<0.001), =6.214; 3.474–11.115; P<0.001) compared group, higher risks adverse outcomes. Conclusions: Combined has better than monitoring or alone surgery.

Language: Английский

Citations

4

Factors Affecting the Prognosis after Primary Tumor Resection for Patients with Metastatic Colorectal Cancer with Synchronous Peritoneal Metastasis: A Multi-center, Prospective, Observational Study DOI Creative Commons

Satoru Kagami,

Kimihiko Funahashi, Hirotoshi Kobayashi

et al.

Journal of the Anus Rectum and Colon, Journal Year: 2025, Volume and Issue: 9(1), P. 134 - 144

Published: Jan. 24, 2025

To clarify the risk factors affecting prognosis after primary tumor resection (PTR) in patients with metastatic colorectal cancer synchronous peritoneal metastasis (mCRC-SPM). Patients were enrolled prospectively JSCCR project "Grading of Peritoneal Seeding Colorectal Cancer." Factors that may influence overall survival-age, sex, location tumor, lymph node metastasis, presence liver degree index (PCI), cure, and postoperative chemotherapy-in PTR group examined using multivariate analysis. Of 133 mCRC-SPM, 112 underwent PTR. Among them, 26 (23.2%) had mCRC-SPM grade P1, 47 (42.0%) P2, 39 (34.8%) P3. The median PCI was 4 (range, 1-28); no surgery-related deaths occurred. Postoperative complications Clavien-Dindo classification ≥grade 2 observed 20 (17.9%) patients. R0 surgery became more difficult as dissemination increased, a significantly better than non-PTR group. In analysis, age ≥75 years, rectal cancer, higher PCI, non-curative resection, non-treatment systemic chemotherapy associated poor are infrequent for P1 localized dissemination, be considered aggressive treatment. including increased reduced survival benefit from

Language: Английский

Citations

0

The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review DOI Creative Commons
Hongxia Cui, Xiao‐Quan Yang, Guangyue Zhao

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: May 1, 2025

Immunotherapy has become the first-line treatment for metastatic mismatch repair deficient (dMMR) colorectal cancer. The efficacy and safety of neoadjuvant immunotherapy non-metastatic dMMR cancer remain unclear. In this article, we explore clinical effect We collected data from databases (PubMed, Wanfang Embase, Cochrane Library, China National Knowledge Infrastructure databases) up to November 2024. primary outcomes major pathological response (MPR), complete (pCR), other were analyzed final results. secondary (pCR rates subgroups) also analyzed. included 21 articles with 628 cancers. A pCR was found in 320/480 (66.6%) patients [effect size (ES): 0.70, 95% CI: 0.66 0.74] fixed-effects model little heterogeneity. MPR 388/452 (85.8%) (ES: 0.86, 0.81 0.91) subgroup analysis, similar T1-T3 group T4a-T4b minimal heterogeneity (OR: 0.76, 0.48 1.22). colon rectal 1.41, 0.39 5.12). Similar immune monotherapy therapy plus chemotherapy 0.74, 0.26 2.10) Neoadjuvant achieves high For locally advanced T4 stage cancer, can still achieve good rates. pCRs rates, avoiding toxic side effects caused by combined dual chemo(radio)therapy. could be another option https://www.crd.york.ac.uk/prospero/, identifier CRD42024594173.

Language: Английский

Citations

0

Surgical and oncological outcomes in transverse colon carcinoma: does tumor sublocation make a difference? DOI Creative Commons

L. Schabl,

Leonardo C. Duraes, Kamil Erözkan

et al.

Langenbeck s Archives of Surgery, Journal Year: 2025, Volume and Issue: 410(1)

Published: May 9, 2025

Language: Английский

Citations

0

Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data DOI Creative Commons
Lichao Cao,

Shenrui Zhang,

Danni Yao

et al.

Aging, Journal Year: 2023, Volume and Issue: 15(14), P. 7098 - 7123

Published: July 21, 2023

In this study, we compared the prognosis, tumor immune microenvironment (TIM), and drug treatment response between left-sided (LCC) right-sided (RCC) colon cancer to predict outcomes in patients with LCC RCC.Based on identified differentially expressed genes using single-cell RNA sequencing data, constructed validated a prognostic model for RCC TCGA-COAD cohort GSE103479 cohort. Moreover, differences of TIM characteristics patients.We five-gene four-gene patients, both showed excellent performance. The higher risk scores were significantly associated greater metastasis (P = 2.6×10-5), N stage 0.012), advanced pathological 1.4×10-4), more stable microsatellite status 0.007) but not T 0.200). For > 0.05). Additionally, infiltration by CD8 regulatory cells M0, M1, M2 macrophages differed < APC TP53 mutations common contrast, KRAS, SYNE1, MUC16 addition, mutation burden values than 5.9×10-8). expression checkpoint targets was 0.05), indicating that maybe sensitive immunotherapy. However, did differ their sensitivity eight selected chemicals or target drugs average half-maximal inhibitory concentrations camptothecin, teniposide, vinorelbine, mitoxantrone lower low-risk high-risk score they these four drugs.We investigated TIM, which may contribute accurate prognosis cancer.

Language: Английский

Citations

6

Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite DOI Creative Commons
Qing Yang, Ruize Qu, Siyi Lu

et al.

International Journal of Medical Sciences, Journal Year: 2024, Volume and Issue: 21(10), P. 1824 - 1839

Published: Jan. 1, 2024

Colorectal cancer is a heterogeneous disease which can be divided into proximal colon cancer, distal and rectal according to the anatomical location of tumor.Each colorectal exhibits distinct characteristics in terms incidence, clinical manifestations, molecular phenotypes, treatment, prognosis.Notably, differs significantly from cancers other subsites.An increasing number studies have highlighted presence unique tumor biological cancer.Gaining deeper understanding these will facilitate accurate diagnosis treatment approaches.

Language: Английский

Citations

2

RCN3 Expression Indicates Prognosis in Colorectal Cancers DOI Open Access

Shengzhe Ma,

Xiaoming Zhu, Xin Cheng

et al.

ONCOLOGIE, Journal Year: 2022, Volume and Issue: 24(4), P. 823 - 833

Published: Jan. 1, 2022

Language: Английский

Citations

7

Incidence of Colorectal Cancer After Intestinal Infection Due to Clostridioides difficile DOI Open Access
Raina Patel,

Matthew Cardeiro,

Lexi Frankel

et al.

World Journal of Oncology, Journal Year: 2024, Volume and Issue: 15(2), P. 279 - 286

Published: March 21, 2024

(

Citations

1

The effect of combined head and tail approach during laparoscopic D3 lymph node dissection on pain severity and complications in patients with right colon cancer DOI

Liang Wang,

Jun Zhao,

Lianghui Shi

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: July 5, 2024

Language: Английский

Citations

1